Multivirus-specific T cells - ViraCyte

Drug Profile

Multivirus-specific T cells - ViraCyte

Alternative Names: Multivirus-specific T cell therapy; Viralym-M

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Herpesvirus infections; Polyomavirus infections

Most Recent Events

  • 22 Aug 2017 Efficacy and adverse events data from a phase II trial in Adenovirus infection, BK virus, Cytomegalovirus, Epstein-barr virus and Human herpes virus released by Viracyte released by ViraCyte
  • 18 Jul 2017 Efficacy data from a phase II trial in Adenovirus infection, BK virus, Cytomegalovirus, Epstein-barr virus and Human herpesvirus released by Viracyte
  • 05 Jul 2017 ViraCyte receives SBIR grant from National Heart, Lung and Blood Institute for T cell immunotherapy development in Polyomavirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top